Management Team

Jenny E. Freeman, M.D.

Co-Founder and CEO, Jenny brings over 25 years of broad hands-on experience in medicine, research and entrepreneurship including cardiothoracic surgery, biomedical research of subcellular processes and medical device innovation. Previously she was founding CEO of HyperMed, Inc., a medical imaging company based on a technology to measure tissue oxygenation.

Alexander Panasyuk, Ph.D

Co-Founder and Chief Technical Officer, Alexander is an established expert in hardware and software integration and data analysis. He is an author on each of Respiratory Motion's patents. Previously, Dr. Panasyuk was the primary development engineer at Hypermed, Inc. His experience includes the Infrared-Optical Telescope Array project at the Harvard-Smithsonian Center for managing a space-born instrument mounted on a Solar & Heliospheric Observatory satellite.

Kamen Bliznashki, M.B.A.

V.P. of Finance and Business Development, Kamen brings investment banking experience from the medical devices, healthcare services, and pharmaceutical industries.  

Malcolm Bock

V.P. of Engineering, Malcolm has over 25 years experience in the medical device industry. Previously he worked at Covidien in their Vascular Therapies Business as Sr. Director of R&D responsible for global development of the DVT Prevention Franchise. Mr. Bock has a successful track record of bringing unique proprietary technology to market successfully. He received the Covidien Inventor of the year award in 2011.

Jack Auer

Jack has over 20 years of experience in the medical device industry. He was most recently Vice President of Marketing and Sales with Xhale Assurance, a start up pulse oximetry sensor company and previously Vice President of Marketing with Oridion Capnography, Inc. (now a Covidien company), a global medical device company that specializes in the development and marketing of capnography capital and consumable products. Prior to Oridion, Jack held senior marketing positions at Siemens Medical Systems USA, Inc. / Draeger Medical Systems, Inc. Jack holds a Bachelor of Arts in Business Administration from the Wharton School at the University of Pennsylvania.

Paul Coss

V.P. Business Development, Paul has over 25 years of critical care and high-level marketing expertise. His broad range of experience includes working at Philips as Director of Marketing, Critical Care Division, in addition to roles in Product Management and Sales.

 

Board of Directors

Jenny Freeman, M.D., Respiratory Motion, CEO

Svetlana Panasyuk, Ph.D., M.B.A.

Dr. Svetlana Panasyuk brings strong software, image processing and algorithm skills critical for R & D efforts. Previously she was instrumental in developing the first clinical hyperspectral systems. Dr. Panasyuk’s training includes a Master’s Degree from Moscow Institute of Technology, a PhD in Physics from Massachusetts Institute of Technology, two Harvard fellowships and an MBA from Babson College. She has subsequently accrued extensive industry experience in all aspects of algorithm and software development, scientific experiment and data processing and the application of these skills toward the development of optical instrumentation and medical devices.

Don Freeman, Ph.D., (no relationship to Dr. Jenny Freeman)

Dr. Freeman brings extensive experience in the business of healthcare and investment banking. Don is an inventor on 20 US patents, has run over 10 life science companies, and served on the Board of Directors of over 20 healthcare companies, public and private. Most recently he was a Board Member of Pluramed, leading to the company’s exit to Sanofi. Before retiring in 2002, Dr. Freeman was President & CEO of HydroCision, a privately owned medical products company. From 1996 until 2000, Dr. Freeman was Chairman, CEO and a Director of RadioMed Corporation, before its acquisition by a major foreign corporation in 2000. Prior to 1996, Dr. Freeman was a Principal of Grayson & Associates, Inc., an investment banking firm specializing in healthcare. Previously, he had roles as President and CEO of Intra-Sonix, Inc., President and CEO of Xenotech and President of Davol, Inc. Following the acquisition of Davol by C. R. Bard, Inc., he served as a Group Vice President of C. R. Bard. Don received his PhD in Chemistry from the University of Maryland and was a Post Doctoral Fellow at Duke University.

Peter Aranow, M.B.A.

Mr. Aranow is the Chairman of Boynton Angels, a Worcester investor group that invests in start-up companies. Peter Aranow has spent 30 years in finance. For 17 years he was in the investment banking department of Bear Stearns & Co., where he worked on debt and equity financings, mergers and acquisitions, and was the investment banker responsible for Bear Stearns’ initial public offering. For the following 13 years he served as chief financial officer for a number of public and privately-owned companies, including an Internet advertising company and the New York City Off-Track Betting Corporation. Mr. Aranow holds an BA from Harvard College and an MBA from Harvard Business School.

Robert J. Manning, M.A.

Mr. Manning serves as Chairman of Cherrystone Angel Group and President of Gray's Point Investments LLC. He is currently a director at Avaxia Biologics and was previously a director at SmartCells, Inc. Mr. Manning retired after more than 25 years with Citibank and Citigroup, where he served as Managing Director and Head of Corporate Finance for Citigroup in Japan where units under his supervision raised more than $50 Billion in private market financings for clients. Mr. Manning served as a senior executive at Citigroup, Inc. He served as Chief of Staff for the U.S. Corporate Finance business of Citibank, before that Global Structured Trade Finance Head and earlier in his career held a variety of product management and country management positions in the U.S., the Middle East, and Africa. Mr. Manning has an M.A. from the Fletcher School of Law and Diplomacy and a B.A. from Brown University in International Relations.

John Friedman, J.D.

Mr. Friedman is the Founding and Managing Partner of Easton Capital Group. Prior to founding Easton Capital, Mr. Friedman was the founder and Managing General Partner of Security Pacific Capital Investors. Security Pacific Capital Investors was a $200-million private equity fund geared towards expansion financings and recapitalizations. Prior to joining Security Pacific, he was a Managing Director and Partner at E.M. Warburg, Pincus & Co., Inc., where he spent eight and a half years. Previously, Mr. Friedman was an attorney with Sullivan and Cromwell. He currently serves on the Boards of Promedior, Trellis Bioscience, Cardiovascular Systems, PreceptiMed, TigerText, Within3, and Precise Light. He was also co-chairman of the President's Council at the Cold Spring Harbor Laboratory and serves as a Trustee of The New Museum of Contemporary Art and The Sculpture Center.